Full-Life Tech and SK Biopharma Ink Pact for Novel Therapeutic

Full-Life Technologies, a globally integrated radiotherapeutics company with facilities in Belgium, Germany, and China, has signed a $571.5 million license agreement with SK Biopharmaceuticals, a worldwide biotech company, for exclusive global clinical research, development, manufacturing, and commercialization rights to Full-Life Technologies’ “FL-091” radiopharmaceutical compound aimed at NTSR1 positive cancers.

This agreement valued at $571.5 million consists of an initial payment, along with progress in development and commercialization, in addition to royalties. In accordance with the agreement, SK Biopharmaceuticals will acquire the NTSR1-targeting Radionuclide Drug Conjugate (RDC) program FL-091, along with its alternate compounds, to be developed and marketed as a novel anti-cancer medication.

FL-091 is a radioligand vector that is a small molecule created to administer focused radiation treatment to cancerous cells by attaching only to NTSR1, a receptor protein. NTSR1 is unusually abundant in different solid tumor types like colorectal, prostate, and pancreatic cancer.

The pharmaceutical firm also possesses the initial opportunity to negotiate for the licensing of additional pre-selected RDC programmes from Full-Life Technologies.

Lanny Sun, CEO of Full-Life Technologies, said, “This agreement with SK Biopharmaceuticals highlights the potential of FL-091 in advancing cancer treatment and demonstrates SK Biopharmaceuticals’ unwavering commitment to building an oncology business around medical innovation. We look forward to future collaborations with SK Biopharmaceuticals, and to leveraging its expertise and resources to advance radiopharmaceutical therapy. The agreement is aligned with our strategic vision of fostering global partnerships and making a meaningful impact on patients worldwide.”